Results 231 to 240 of about 18,059 (296)

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.

Bioorganic chemistry (Print), 2023
Ticlopidine is an antithrombotic prodrug of the thienotetrahydropyridine family. For platelet inhibition it has to undergo oxidative ring-opening by cytochrome P450 enzymes.
Chunyang Bi, Laura Schäkel, Salahuddin Mirza, Katharina Sylvester, J. Pelletier, Sang-Yong Lee, Thanigaimalai Pillaiyar, J. Sévigny, C. Müller   +8 more
semanticscholar   +1 more source

Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.

Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy, 2019
BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode.
G. Belcaro, M. Dugall, Hugh D Bradford, M. Cesarone, B. Feragalli, C. Gizzi, R. Cotellese, Shu Hu, P. Rodriguez, M. Hosoi   +9 more
semanticscholar   +1 more source

Ticlopidine-Induced Lupus

JCR: Journal of Clinical Rheumatology, 2001
Ticlopidine is a widely used drug for prevention of stroke and other serious vascular events with a multitude of possible side effects. An increasing number of drugs are being recognized as the triggering agents of drug-induced lupus. We describe three patients in whom the etiologic connection between ticlopidine and lupus was supported by the ...
Alexandra Balbir-Gurman, Daniel Schapira, Ronit Sevilia, Yolanda Braun-Moscovici, Abraham Menahem Nahir   +4 more
openaire   +3 more sources

Thienopyridine (Ticlopidin, Clopidogrel) [PDF]

Hämostaseologie, 1998
ZusammenfassungThienopyridine (Ticlopidin und Clopidogrel) hemmen spezifisch die ADP-medi- ierten Mechanismen der Thrombozytenaktivierung. Der genaue molekulare Wirkmechanismus der Thrombozytenfunktionshemmung durch Thienopyridine ist nicht bekannt.
A.-A. Weber, K. Schrör
openaire   +1 more source

HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors.

Chemical Research in Toxicology, 2018
The HLA class I allele HLA-A*33:03 is a risk factor for ticlopidine-induced liver injury. Herein, we show HLA class I-restricted ticlopidine-specific CD8+ T-cell activation in healthy donors expressing HLA-A*33:03.
Toru Usui, A. Tailor, L. Faulkner, Xiaoli Meng, J. Farrell, A. Daly, G. Dear, B. Park, D. Naisbitt   +8 more
semanticscholar   +1 more source

Delayed Neutropenia with Ticlopidine

Annals of Pharmacotherapy, 1994
OBJECTIVE: To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug. CASE SUMMARY: A 68-year-old woman was placed on ticlopidine after a transient ischemic attack. Ten days later the drug was discontinued because the patient developed a rash.
Lori A. Hansen, Debra K Farver
openaire   +3 more sources

Ticlopidine-induced thrombocytopenia

The Netherlands Journal of Medicine, 1999
A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine. Ticlopidine was prescribed following coronary artery stenting. The patient recovered rapidly after discontinuation of the drug, suggesting a possible relationship between ticlopidine and thrombocytopenia ...
A. Loualidi, C.J. de Vries, J.J. Koornstra   +2 more
openaire   +3 more sources

Ticlopidine-theophylline interaction

Clinical Pharmacology and Therapeutics, 1987
Ticlopidine, a new antithrombotic agent, and theophylline, a widely used bronchodilator drug, are both almost completely metabolized in the liver. To evaluate an interaction between these two drugs, we studied theophylline pharmacokinetics before, after 10 days of ticlopidine administration, and 1 month later in 10 healthy volunteers. We found a highly
Roberto Parravicini, Gian Maria Elli, Guglielmo Buccino, Agostino Colli, Giancarlo Scaltrini, Massimo Cocciolo   +5 more
openaire   +3 more sources

The mechanisms of action of ticlopidine

Thrombosis Research, 1983
anti-platelet drug which was discovered in the laboratories of Parcor-Sanofi, Toulouse, France. This drug whose properties have been recently reviewed (1) has the potential as a clinically useful antithrombotic agent. It inhibits platelet aggregation induced by ADP and other aggregating agents (2).
openaire   +3 more sources